Repotrectinib is a ROS1 Inhibitor for ROS1-positive Non-small Cell Lung Cancer Research
On November 16, 2023, the U.S. Food and Drug Administration has approved Repotrectinib. Repotrectinib is indicated for the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell…